Proceeds to fund advanced development of Company’s delivery system for preservative-free ophthalmic drugs
TearClear, the eye health technology company uniquely focused on developing a safe and reliable means of delivering preservative-free topical ophthalmic drugs, today announced the completion of its Series A financing, with proceeds totaling $4.5 million. The round was co-led by Visionary Venture Fund and Bluestem Capital. The financing will provide sufficient capital to advance the development of TearClear’s filter technology, the first and only system to assure the safe delivery of a preservative-free drop from preserved, multi-dose products.
In addition, the Company has assembled a team of accomplished ophthalmology veterans to drive forward the development of its filter technology, including William Link, Ph.D., who has significant executive and investment expertise in ophthalmology and has been appointed to the Board of Directors.
The company’s innovative chemical filter removes benzalkonium chloride (BAK) at the point of instillation, allowing multi-dose product preservation until the moment of application. BAK is the most common preservative used in multi-dose topical ophthalmic drugs for the treatment of glaucoma, over-the-counter (OTC) dry-eye, and allergic conjunctivitis.
Richard Lindstrom, MD, an internationally recognized leader in corneal, cataract, refractive and laser surgery, commented, “BAK has been shown to be a significant cause of a host of adverse events with prolonged use, including ocular discomfort, glaucoma surgery failure, conjunctival inflammation, and fibrosis, tear film instability, corneal cytotoxicity, and anterior chamber inflammation. TearClear’s technology offers a compelling and differentiated approach to eliminating the preservative before delivery while allowing it to preserve sterility within the bottle.”
TearClear’s leadership team is comprised of globally recognized leaders in ophthalmic product development, medical practice and chemical manufacturing, including:
- Rick Heinick is Chairman of the Board. Mr. Heinick brings both entrepreneurial and corporate expertise through previous experience as CEO of early-stage ophthalmic businesses and an Executive Vice President at Bausch + Lomb.
- Kevin Hershfield has been appointed Chief Executive Officer. Mr. Hershfield formerly led chemical manufacturing and distribution businesses supporting medical and industrial markets.
- Richard D’Souza, Ph.D., formerly Head of Research & Development for Bausch + Lomb, has been appointed Chief Science & Technology Officer.
- Howard Golub, MD, Ph.D., founder and CEO of multiple medical diagnostic companies including Care-Safe LLC, has been appointed Head of Clinical Development.
Kevin Hershfield stated, “TearClear’s technology creates immediate value for topical ophthalmic drugs that comprise a $10 billion market worldwide. By reliably and efficiently keeping BAK in the bottle but out of the eye, we are able to directly influence improved global eye health.”
Rick Heinick added, “This investment by Visionary Ventures, a fund comprised of leading ophthalmologists and venture experts, and Bluestem Capital, a team of deeply knowledgeable healthcare investors, is an important validation of our technology and recognition of the prevalent therapeutic need we aim to address. We look forward to future achievements together.”
TearClear is an emerging ophthalmic pharmaceutical company with the goal of disrupting the way current topical medications are delivered to the ocular surface. Our lead product candidates in glaucoma will pave the way for future indications across multiple programs in development. This first-in-class platform of drugs enables medication delivery to ultimately enhance patient safety and compliance by capturing preservatives before they reach the ocular surface.
About Preservative Free
Preservatives, such as benzalkonium chloride (BAK), are necessary for ophthalmic solutions to maintain sterility. However, on the ocular surface, they have been reported to be associated with adverse effects like hyperemia, tear film instability, and conjunctival inflammation potentially leading to meibomian gland dysfunction (MGD). By removing preservatives from the ocular surface, the potential for long-term deleterious effects on the eye is reduced. TearClear offers the only means of delivering a preservative-free dose directly from preserved solutions.
TearClear Press Contact
- Patrick Crowley